Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Melanoma: early-phase trial registry
14 of 22 indexed Advanced Melanoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #756 of 28,707 conditions by registered trial count.
22 US clinical trials · 14 currently recruiting · #756 of 28,707 conditions by registered trial count
Advanced Melanoma: 22 US clinical trials tracked, 14 recruiting.
Advanced Melanoma is the subject of 22 registered US clinical trials on ClinicalTrials.gov, 14 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition advanced-melanoma
OPEN 14 | RECR 64% | LATE 3 | EARLY 18 | RANK #756 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Autoimmune Disease (64% recruiting · 11 trials)
Advanced Melanoma lists 14 open slots (64% of 22 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Melanoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Melanoma is recruiting above its size-band peers.
14 of 22 indexed trials (63.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Advanced Melanoma trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 3 of 22 trials (13.6%). 18 distinct sponsors appear on at least one study for this condition label.
-
Typical Advanced Melanoma enrolment sits around 88 participants.
Median target enrolment is 88 among the 22 trials that report a genuine target (sentinel values excluded). 13 of those (59.1%) plan for fewer than 100 participants.
-
Advanced Melanoma research is mostly interventional.
22 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
22 total, page 1 of 1
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Eikon Therapeutics
NCT06697301
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Immunocore
NCT06112314
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Immunocore
NCT05549297
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Replimune
NCT06264180
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
University of California, Davis
NCT05967533
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT06295159
A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
Memorial Sloan Kettering Cancer Center
NCT06594991
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
NCT05039801
AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Yale University
NCT07027488
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
Dana-Farber Cancer Institute
NCT06298734
Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
Washington University School of Medicine
NCT05629546
A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma
Yana Najjar
NCT03311308
Naltrexone and Propranolol Combined With Immunotherapy
Sarah Weiss
NCT05968690
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
University of Virginia
NCT06472661
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT01134614
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
Agenus
NCT05529316
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
ECOG-ACRIN Cancer Research Group
NCT04462406
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
National Cancer Institute (NCI)
NCT02965716
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
Yale University
NCT04495257
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
Roswell Park Cancer Institute
NCT02650986
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
NCT04514484
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)
Merck Sharp & Dohme
NCT03776136
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 8 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Melanoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Melanoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Melanoma page
22 registered trials, 14 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 14 Advanced Melanoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Advanced Melanoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Melanoma condition card totals 22 registered trials; most-linked intervention Nivolumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.